Published in Blood on April 20, 2009
Hepcidin and iron homeostasis. Biochim Biophys Acta (2012) 2.96
The role of hepcidin in iron metabolism. Acta Haematol (2009) 1.88
Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol (2011) 1.75
Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica (2009) 1.51
Mechanisms of mammalian iron homeostasis. Biochemistry (2012) 1.51
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
Iron homeostasis and the inflammatory response. Annu Rev Nutr (2010) 1.40
The liver: conductor of systemic iron balance. Blood (2013) 1.30
Expression and function of iron-regulatory proteins in retina. IUBMB Life (2010) 1.03
Hepcidin in the diagnosis of iron disorders. Blood (2016) 0.93
Out of balance--systemic iron homeostasis in iron-related disorders. Nutrients (2013) 0.92
Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation. Nutrients (2015) 0.82
Hepcidin bound to α2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. J Biol Chem (2013) 0.79
Mice with hepcidin-resistant ferroportin accumulate iron in the retina. FASEB J (2015) 0.79
Hepcidin-minireview. J Clin Diagn Res (2013) 0.78
Chronic inflammation and iron metabolism. J Pediatr (2015) 0.77
Hepcidin in neoplastic disease. J Med Life (2013) 0.77
Laboratory use of hepcidin in renal transplant recipients. Biochem Med (Zagreb) (2016) 0.76
Renal Handling of Circulating and Renal-Synthesized Hepcidin and Its Protective Effects against Hemoglobin-Mediated Kidney Injury. J Am Soc Nephrol (2016) 0.76
Duodenal expression of iron transport molecules in patients with hereditary hemochromatosis or iron deficiency. J Cell Mol Med (2012) 0.76
Is erythroferrone finally the long sought-after systemic erythroid regulator of iron? World J Biol Chem (2015) 0.75
Uncoupled iron homeostasis in type 2 diabetes mellitus. J Mol Med (Berl) (2017) 0.75
Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science (2007) 4.89
Iron overload in human disease. N Engl J Med (2012) 3.77
Mitochondrial remnant organelles of Giardia function in iron-sulphur protein maturation. Nature (2003) 3.38
Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat (2007) 2.73
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22
Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood (2004) 2.12
Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A (2010) 2.02
Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96
The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta (2002) 1.86
New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr (2004) 1.71
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood (2004) 1.67
Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66
Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood (2004) 1.62
Direct interorganellar transfer of iron from endosome to mitochondrion. Blood (2007) 1.59
Heme oxygenase 1 is expressed in murine erythroid cells where it controls the level of regulatory heme. Blood (2014) 1.59
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis (2006) 1.49
Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics (2008) 1.49
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One (2013) 1.46
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43
Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol (2008) 1.43
Mitochondrial-type assembly of FeS centers in the hydrogenosomes of the amitochondriate eukaryote Trichomonas vaginalis. Proc Natl Acad Sci U S A (2004) 1.43
The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol (2002) 1.40
Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia. Hum Mutat (2009) 1.39
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol (2003) 1.38
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38
Defensins and the convergent evolution of platypus and reptile venom genes. Genome Res (2008) 1.37
The N-terminal tail of hERG contains an amphipathic α-helix that regulates channel deactivation. PLoS One (2011) 1.35
The long history of iron in the Universe and in health and disease. Biochim Biophys Acta (2011) 1.33
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A (2009) 1.31
Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem (2006) 1.30
Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res (2003) 1.30
Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 1.29
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res (2006) 1.28
Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res (2011) 1.28
Translational efficiency in patients with Diamond-Blackfan anemia. Haematologica (2006) 1.25
Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A (2009) 1.25
Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25
Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol (2008) 1.24
AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther (2009) 1.22
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22
Characteristics of Gloeophyllum trabeum alcohol oxidase, an extracellular source of H2O2 in brown rot decay of wood. Appl Environ Microbiol (2007) 1.21
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21
Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab (2013) 1.21
Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology (2002) 1.18
Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallogr C (2003) 1.17
Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem (2005) 1.17
The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis (2011) 1.17
Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal (2012) 1.16
S-nitrosylation of IRP2 regulates its stability via the ubiquitin-proteasome pathway. Mol Cell Biol (2004) 1.16
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood (2006) 1.15
Nitrogen monoxide-mediated control of ferritin synthesis: implications for macrophage iron homeostasis. Proc Natl Acad Sci U S A (2002) 1.14
Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13
The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J (2009) 1.12
Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol (2004) 1.11
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics (2002) 1.11
The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics. Eur Biophys J (2003) 1.11
Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol (2011) 1.11
Targeted gene replacement of a ferredoxin gene in Trichomonas vaginalis does not lead to metronidazole resistance. Mol Microbiol (2004) 1.10
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal (2012) 1.09
The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS Lett (2002) 1.09
Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data. J Biol Chem (2010) 1.08
Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic alpha-helix in C-type inactivation. J Biol Chem (2003) 1.08
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol (2012) 1.08
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol (2008) 1.07
Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis. PLoS One (2009) 1.07
Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol (2011) 1.07
Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab (2013) 1.06
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci U S A (2006) 1.06
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem (2010) 1.05
Knock-downs of iron-sulfur cluster assembly proteins IscS and IscU down-regulate the active mitochondrion of procyclic Trypanosoma brucei. J Biol Chem (2006) 1.05
Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol (2009) 1.05
The Psb27 assembly factor binds to the CP43 complex of photosystem II in the cyanobacterium Synechocystis sp. PCC 6803. Plant Physiol (2011) 1.04
The Gárdos channel: a review of the Ca2+-activated K+ channel in human erythrocytes. Int J Biochem Cell Biol (2003) 1.03
Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood (2004) 1.03
The pore domain outer helix contributes to both activation and inactivation of the HERG K+ channel. J Biol Chem (2008) 1.03
Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2009) 1.03
Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem (2009) 1.03
In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood (2006) 1.02